Abstract
BackgroundThe ABO blood group is reported to be associated with the incidence and patient survival for several types of malignancies. We conducted a retrospective study to evaluate the prognostic significance of the ABO blood group in patients with resected non-small cell lung cancer (NSCLC).MethodsA total of 333 patients (218 men and 115 women) with resected NSCLC were included in this study. In addition to age, sex, smoking status, preoperative serum carcinoembryonic antigen (CEA) level, operative procedure, histology of tumors, pathological stage (p-stage), and adjuvant therapy, the association between the ABO blood group and survival was explored.ResultsThe 5-year overall and disease-free survival rates were 83.0% and 71.6% for blood group O, 67.2% and 62.3% for blood group A, 68.8% and 68.8% for blood group B and 69.2% and 65.3% for blood group AB, respectively. A multivariate analysis for overall survival showed the ABO blood group (group A vs. group O: HR 2.47, group AB vs. group O: HR 3.62) to be an independent significant prognostic factor, in addition to age, sex, smoking status, p-stage, and serum CEA level. A multivariate analysis for disease-free survival also showed the ABO blood group to be an independent significant prognostic factor.ConclusionsThe ABO blood group is an independent prognostic factor in patients with resected NSCLC. Studies of other larger cohorts are therefore needed to confirm the relationship between the ABO blood group and the prognosis among patients with resected NSCLC.
Highlights
Lung cancer is the leading cause of cancer death worldwide
In order to improve the outcomes of surgically managed patients, new prognostic factors must be explored, in addition to established factors such as a high preoperative or postoperative serum carcinoembryonic antigen (CEA) level,[3,4] positive results on pleural lavage cytology,[5] and a high standardized uptake value on positron emission tomography.[6]
An increasing number of studies have shown that the ABO blood group, in addition to its fundamental role in transfusion medicine, plays an important role in several human diseases, including venous thromboembolism (VTE),[7] coronary heart disease,[8] ischemic stroke,[9] and neoplastic disorders
Summary
Lung cancer is the leading cause of cancer death worldwide. In 2008, 1.6 million people received a new diagnosis of lung cancer, comprising 13% of all new cancer diagnoses, and 1.37 million people died of lung cancer, accounting for 18% of all cancer deaths in the world.[1,2] Patients with lung cancer, especially non-small cell lung cancer (NSCLC) without metastatic disease, are considered to be candidates for surgical resection. We conducted a retrospective study to evaluate the prognostic significance of the ABO blood group in patients with resected non-small cell lung cancer (NSCLC). Sex, smoking status, preoperative serum carcinoembryonic antigen (CEA) level, operative procedure, histology of tumors, pathological stage (p-stage), and adjuvant therapy, the association between the ABO blood group and survival was explored. A multivariate analysis for overall survival showed the ABO blood group (group A vs group O: HR 2.47, group AB vs group O: HR 3.62) to be an independent significant prognostic factor, in addition to age, sex, smoking status, p-stage, and serum CEA level. A multivariate analysis for disease-free survival showed the ABO blood group to be an independent significant prognostic factor. Conclusions: The ABO blood group is an independent prognostic factor in patients with resected NSCLC.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
